Stay updated on BLASST-1: Nivolumab Combo in MIBC Clinical Trial

Sign up to get notified when there's something new on the BLASST-1: Nivolumab Combo in MIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BLASST-1: Nivolumab Combo in MIBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:12:59.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification in the data related to the clinical trial BLASST-1 (Bladder Cancer Signal Seeking Trial) involving the combination treatment of Nivolumab, Gemcitabine, and Cisplatin in patients with Muscle Invasive Bladder Cancer (MIBC) undergoing cystectomy.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:17.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. The new description also includes a link for general information about clinical research.
    Difference
    53%
    Check dated 2024-05-22T20:34:04.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T23:11:09.000Z thumbnail image

Stay in the know with updates to BLASST-1: Nivolumab Combo in MIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BLASST-1: Nivolumab Combo in MIBC Clinical Trial page.